About Benitec Biopharma Limited
Benitec Biopharma Limited is a company based in Sydney (Australia) founded in 1997.. The company has 16 employees as of June 30, 2024. Benitec Biopharma Limited has completed 1 acquisition, including Tacere Therapeutics. Benitec Biopharma Limited offers products and services including ddRNAi Technology. Benitec Biopharma Limited operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Sydney, Australia
- Employees 16 as on 30 Jun, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Benitec Biopharma Inc.
-
Annual Revenue
$0-100as on Jun 30, 2024
-
Net Profit
$-21.75 M-11.19as on Jun 30, 2024
-
EBITDA
$-22.25 M-19.01as on Jun 30, 2024
-
Latest Funding Round
$40 M (USD), Post-IPO
Apr 22, 2024
-
Investors
-
Employee Count
16
as on Jun 30, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Benitec Biopharma Limited
Benitec Biopharma Limited is a publicly listed company on the NASDAQ with ticker symbol BNTC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Benitec Biopharma Limited
Benitec Biopharma Limited offers a comprehensive portfolio of products and services, including ddRNAi Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables permanent gene silencing for treating human diseases through RNA interference.
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Benitec Biopharma Limited
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $40.0M
-
First Round
First Round
(24 Feb 2014)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2024 | Amount | Post-IPO - Benitec Biopharma Limited | Valuation |
investors |
|
| Sep, 2019 | Amount | Post-IPO - Benitec Biopharma Limited | Valuation |
investors |
|
| Feb, 2014 | Amount | Post-IPO - Benitec Biopharma Limited | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Benitec Biopharma Limited
Benitec Biopharma Limited has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tacere Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
RNAi therapeutics for the treatment of serious infectious diseases such as Hepatitis C
|
2006 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Benitec Biopharma Limited
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Benitec Biopharma Limited Comparisons
Competitors of Benitec Biopharma Limited
Benitec Biopharma Limited operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Benitec Biopharma Limited
Frequently Asked Questions about Benitec Biopharma Limited
When was Benitec Biopharma Limited founded?
Benitec Biopharma Limited was founded in 1997 and raised its 1st funding round 17 years after it was founded.
Where is Benitec Biopharma Limited located?
Benitec Biopharma Limited is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
How many employees does Benitec Biopharma Limited have?
As of Jun 30, 2024, the latest employee count at Benitec Biopharma Limited is 16.
What does Benitec Biopharma Limited do?
Benitec Biopharma Limited was founded in 1997 in Sydney, Australia, within the biopharmaceutical sector. RNAi-based therapies targeting infectious, ocular, and genetic diseases are developed using ddRNAi technology, which integrates gene silencing and gene therapy. An internal pipeline features four drug candidates addressing hepatitis B, hepatitis C, age-related macular degeneration, and oculopharyngeal muscular dystrophy, including BB-301 and BB-103 for the latter two conditions.
Who are the top competitors of Benitec Biopharma Limited?
Benitec Biopharma Limited's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Benitec Biopharma Limited offer?
Benitec Biopharma Limited offers ddRNAi Technology.
Is Benitec Biopharma Limited publicly traded?
Yes, Benitec Biopharma Limited is publicly traded on NASDAQ under the ticker symbol BNTC.
How many acquisitions has Benitec Biopharma Limited made?
Benitec Biopharma Limited has made 1 acquisition, including Tacere Therapeutics.
What is Benitec Biopharma Limited's ticker symbol?
The ticker symbol of Benitec Biopharma Limited is BNTC on NASDAQ.